News

Pharma’s Almanac | What do you think most differentiates the U.S. pharma/biopharma industry or the market?

Paradigm4’s Marilyn Matz reflects on the understanding complex biological phenomena has required concurrent advances in experimental methods and computing power.

whitepages icon x

The Analytical Scientist | The Vast Potential of Single-Cell Analysis

Single-cell analysis has great promise… but how can we get there? by Zachary Pitluk

whitepages icon x

GenomeWeb: Paradigm4 Moves Into Single-Cell Data, Helps Pharma Address COVID-19

Neil Versel

whitepages icon x

LABIOTECH || Partnership between Paradigm4 and Alnylam accelerates drug target discovery

New genetically-validated drug targets are found at accelerated speed using population scale biobank genotype-phenotype datasets after a foundational partnership is formed between Paradigm4 and Alnylam.